Aclaris Therapeutics
ACRS
82 hedge funds and large institutions have $198M invested in Aclaris Therapeutics in 2020 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 7 closing their positions.
1,181% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $240K
357% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 7
205% more capital invested
Capital invested by funds: $65M → $198M (+$133M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
44% more funds holding
Funds holding: 57 → 82 (+25)
14.59% more ownership
Funds ownership: 59.82% → 74.4% (+15%)
32% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$8.25M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$3.95M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$3.4M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$2.74M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.34M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$1.48M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.29M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.05M |
| 5 |
TI
Telemetry Investments
New York
|
-$931K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
76
Panagora Asset Management
Boston,
Massachusetts
| $5K | +$3.27K | +774 | New |
|
77
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $3K | – | – | – |
|
|
IA
78
IFP Advisors
Tampa,
Florida
| $3K | +$2.11K | +500 | New |
|
|
TRCT
79
Tower Research Capital (TRC)
New York
| $2K | +$1.15K | +273 | New |
|
|
QT
80
Quantbot Technologies
New York
| $1K | +$844 | +200 | New |
|
|
AIM
81
Alambic Investment Management
Belvedere,
California
| – | -$154K | -59,766 | Closed |
|
|
WG
82
Winton Group
London,
United Kingdom
| – | -$122K | -47,559 | Closed |
|
83
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$81K | -31,575 | Closed |
|
84
Tudor Investment Corp
Stamford,
Connecticut
| – | -$53K | -20,750 | Closed |
|
|
LP
85
LMR Partners
London,
United Kingdom
| – | -$29K | -11,420 | Closed |
|
ACRS Hedge Fund Activity: Q4 2020 in Review
82 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2020, worth a combined $198M — up 205% from $65M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ACRS positions and 7 closed out — a net gain of 25 holders — while 15 added to existing stakes and 22 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $8.25M. The largest seller was Samsara BioCapital, cutting an estimated $3.34M.
- 82 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2020, up from 57 in Q3 2020.
- Funds reported $198M of Aclaris Therapeutics stock for Q4 2020, up 205% quarter-over-quarter.
- 32 funds opened new Aclaris Therapeutics positions in Q4 2020 and 7 closed out, a net change of +25 holders.
- The largest Aclaris Therapeutics buyer in Q4 2020 was VR Adviser, an estimated $8.25M added.
- The largest Aclaris Therapeutics seller in Q4 2020 was Samsara BioCapital, an estimated $3.34M sold.
Based on aggregated 13F filings for Q4 2020.